Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).
1 finding from 1 review
Failure to maintain clinical remission at end of study · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.73 [0.63, 0.85]
Studies not reported
Moderate
Failure to maintain clinical response · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol probably leads to lower failure to maintain clinical response at week 26(1 RCT, 428… compared with placebo (moderate certainty).
1 finding from 1 review
RR 0.58 [0.48, 0.71]
Studies not reported
Moderate
Any severe adverse event during maintenance treatment · people with Crohn's disease who responded to CZP remission‐induction treatment
Certolizumab pegol showed no clear difference in serious adverse events during remission maintenance treatment(1 RCT,… compared with placebo (low certainty).
1 finding from 1 review
RR 0.84 [0.4, 1.78]
Studies not reported
Low
Clinical remission · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical remission compared with placebo (moderate certainty).
1 finding from 1 review
Clinical response · Patients with active Crohn's disease
Certolizumab pegol probably leads to higher clinical response compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · Patients with active Crohn's disease
Certolizumab pegol showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review